FDA Approves New Psoriasis Drug

Siliq will be used to treat adults with moderate-to-severe plaque psoriasis

According to a news release, the FDA has approved Siliq to treat adults with moderate-to-severe plaque psoriasis. It is administered as an injection.

The drug will be used by patients for whom other methods, such as systemic therapy and phototherapy, have failed.

"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment."

Siliq’s active ingredient, brodalumab, binds to a protein that causes inflammation, preventing it from occurring.

OH&S Digital Edition

  • OHS Magazine Digital Edition - November 2017

    November 2017

    Featuring:

    • HEAD & FACE PROTECTION
      Key to Effective Head & Face Protection
    • CONFINED SPACES
      Confined Space: Preparing for Rescue
    • FALL PROTECTION
      Are You Fully Prepared?
    • TRAINING
      Microlearning: Training for the Millennial Generation
    View This Issue

comments powered by Disqus